Sumatriptan

Half-Life (t½)
PO: 1.8h · SC: 2h
Formula
C14H21N3O2S
Molecular Weight
295.4 g/mol
PubChem CID
5358
Aliases
Imitrex

Pharmacological Mechanism

5-HT1B/1D agonist — constricts cranial blood vessels and inhibits trigeminal nerve neuropeptide release. First-line abortive migraine therapy. Coronary vasoconstriction concern in CAD. SC formulation has fastest onset (~10 min).

Half-Life & Elimination Curve (PO: 1.8h · SC: 2h)

100%50%25%12.5%0%0h0×t½1.8h1×t½3.6h2×t½5.4h3×t½7.2h4×t½9h5×t½0×t½ (0h): 100% remaining (~19.8 µg/L)1×t½ (1.8h): 50% remaining (~9.91 µg/L)2×t½ (3.6h): 25% remaining (~4.96 µg/L)3×t½ (5.4h): 12.5% remaining (~2.48 µg/L)4×t½ (7.2h): 6.3% remaining (~1.24 µg/L)5×t½ (9h): 3.1% remaining (~0.62 µg/L)
Plasma (PO)t½ Decay (1.8h)Effect Site (ke0)
  • 0×t½0h100% (19.8 µg/L)
  • 1×t½1.8h50% (9.91 µg/L)
  • 2×t½3.6h25% (4.96 µg/L)
  • 3×t½5.4h12.5% (2.48 µg/L)
  • 4×t½7.2h6.3% (1.24 µg/L)
  • 5×t½9h3.1% (0.62 µg/L)
Elimination t½1.8h (PO)
Rate Constant (ke)0.385 h⁻¹
Time to Peak (Tmax)1.9h
Est. Peak (Cmax)19.8 µg/L
Clearance (CL)65.5 L/h
97% Washout (5×t½)9h

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References